Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

Movement Disorders

Volumn 29, Issue 6, 2014, Pages 772-779

  Ko, Wai Kin D ^a,b,c   Pioli, Elsa ^a   Li, Qin ^d   Mcguire, Steve ^a   Dufour, Audrey ^e   Sherer, Todd B ^e   Bezard, Erwan ^a,b,c   Facheris, Maurizio F ^e  

^a Williams House   (United Kingdom)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^d INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^e THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

Author keywords

Dyskinesia; Macaque; MGluR5 antagonist; Parkinson

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; FENOBAM; LEVODOPA; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDYSKINETIC EFFECT; ARTICLE; CHOREA; CONTROLLED STUDY; DRUG EFFECT; DYSKINESIA; DYSTONIA; FEMALE; LEVODOPA INDUCED DYSKINESIA; LOCOMOTION; LOW DRUG DOSE; NONHUMAN; PARKINSON DISEASE; PARKINSONIAN EFFECT; PRIMATE; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DYSKINESIA, DRUG-INDUCED; MACACA FASCICULARIS; MPTP POISONING;

AMANTADINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; IMIDAZOLES; LEVODOPA; MACACA FASCICULARIS; MPTP POISONING;

EID: 84899959209     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25859     Document Type: Article

References (45)

1. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
2. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.
3. Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol 2000;247:II36-II42.
4. Calabresi P, Di Filippo M, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 2008;23(Suppl 3):S570-S579.
5. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991;206:297-300.
6. Kornhuber J, Schoppmeyer K, Riederer P. Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci Lett 1993;163:129-131.
7. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 1996;8:446-454.
8. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 2005;25:3312-3322.
9. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999;56:1383-1386.
10. Luginger E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:873-878.
11. Macchio GJ, Ito V, Sahgal V. Amantadine-induced coma. Arch Phys Med Rehabil 1993;74:1119-1120.
12. Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol 1987;10:522-526.
13. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:141-143.
14. Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 2010;25:1357-1363.
15. Samadi P, Gregoire L, Morissette M, et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 2008;29:1040-1051.
16. Ouattara B, Gregoire L, Morissette M, et al. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 2011;32:1286-1295.
17. Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 2007;101:483-497.
18. Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 2009;330:227-235.
19. Porter RH, Jaeschke G, Spooren W, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005;315:711-721.
20. Rylander D, Iderberg H, Li Q, et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 2010;39:352-361.
21. Berry-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009;46:266-271.
22. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;21:6853-6861.
23. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-767.
24. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005;57:17-26.
25. Guigoni C, Li Q, Aubert I, et al. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3, 4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci 2005;25:2102-2107.
26. Gold SJ, Hoang CV, Potts BW, et al. RGS9-2 negatively modulates L-3, 4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci 2007;27:14338-14348.
27. Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E. A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. Mov Disord 2012;27:1373-1378.
28. Brotchie JM, Fox SH. Quantitative assessment of dyskinesias in subhuman primates. Mov Disord 1999;14(Suppl 1):40-47.
29. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
30. Jacob W, Gravius A, Pietraszek M, et al. The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning. Neuropharmacology 2009;57:97-108.
31. Wu WN, McKown LA, O'Neill PJ. In vitro and in vivo metabolism of the antianxiolytic agent fenobam in the rat. J Pharm Sci 1995;84:185-189.
32. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 1982;2:129-133.
33. Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 2010;333:865-873.
34. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26:1243-1250.
35. Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013;28:1838-1846.
36. Bezard E, Munoz A, Tronci E, et al. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia. Neurosci Res 2013;77:242-246.
37. Sawada H, Oeda T, Kuno S, et al. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PloS One 2010;5:e15298.
38. Dunah AW, Wang Y, Yasuda RP, et al. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 2000;57:342-352.
39. Hallett PJ, Dunah AW, Ravenscroft P, et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005;48:503-516.
40. Hurley MJ, Jackson MJ, Smith LA, Rose S, Jenner P. Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. Eur J Neurosci 2005;21:3240-3250.
41. Pisani A, Calabresi P, Centonze D, Bernardi G. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol 1997;120:1007-1014.
42. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 2000;20:7871-7879.
43. Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 2004;29:1259-1269.
44. Pisani A, Gubellini P, Bonsi P, et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 2001;106:579-587.
45. Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E. Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model. Mov Disord 2013;28:663-667.